Biotechnology - Neurological, Markets & Marketing


Popular Filters

Forward Pharma sues Biogen Idec over Tecfidera sales in Germany


Danish biopharmaceutical company Forward Pharma has filed a law suit against US biotech major Biogen…

Biogen IdecBiotechnologyForward PharmaGermanyLegalMarkets & MarketingNeurologicalTecfidera

Lundbeck and Otsuka partner on Biotie’s nalmefene in Japan

Lundbeck and Otsuka partner on Biotie’s nalmefene in Japan


Biotie Therapies says that its partner, Lundbeck has expanded its existing alliance with Otsuka Pharmaceutical…

Asia-PacificBiotechnologyBiotie TherapiesLicensingLundbeckMarkets & MarketingnalmefeneNeurologicalSelincro

New entrants to multiple sclerosis market will drive 10% pa growth through 2018


The market for disease-modifying multiple sclerosis (MS) therapies will expand at an annual rate of 10%…

AbbVieAubagioBayerBiogen IdecBiotechnologydaclizumabGlobalLemtradaMarkets & MarketingNeurologicalocrelizumabPharmaceuticalRocheSanofiTecfidera

Biogen Idec sees EU launch delay for Tecfidera on patent issues


In a filing with the Securities and Exchange Commission, US biotech firm Biogen Idec (Nasdaq: BIIB) said…

Biogen IdecBiotechnologyEuropeMarkets & MarketingNeurologicalPatentsRegulationTecfidera

Appeals Court rules against EMD Serono over Rebif deal with Pfizer


Germany's Merck KGaA (MRK: DE) says that a Pennsylvania appeals court has ruled against Merck in deciding…

BiotechnologyEMD SeronoLegalMarkets & MarketingMerck KGaANeurologicalNorth AmericaPfizerPharmaceuticalRebif

Growing US uptake of Genzyme's Aubagio at three months post-launch


Some 34% of surveyed US neurologists have prescribed French drug major Sanofi (Euronext: SAN) subsidiary…

AubagioBiotechnologyGenzymeMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalSanofi

Genzyme says Lemtrada sBLA for MS accepted by FDA; reports on Aubagio


French drug major Sanofi (Euronext: SAN) US biotech subsidiary Genzyme says that the US Food and Drug…

AubagioBiotechnologyGenzymeLemtradaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

Pain therapies sales to exceed $49 billion in 2026, driven by new product launches


The market for pain therapies will grow at an annual rate of 1.8% over the next 15 years, surpassing…

BiotechnologyfulranumabGlobalJohnson & JohnsonMarkets & MarketingNeurologicalPfizerPharmaceuticalTakeda Pharmaceuticalstanezumabtapentadol

Novartis' Gilenya MS patient share growth in Europe likely driven by improved product satisfaction and efficacy-related


Swiss drug major Novartis' (NOVN: VX) Gilenya (fingolimod) has captured 5.4% of those multiple sclerosis…

AubagioBG-12Biogen IdecBiotechnologyEuropeGilenyaMarkets & MarketingNeurologicalNovartisPharmaceuticalSanofi

US multiple sclerosis market growth remains centered on Tysabri and Gilenya ahead of Aubagio's launch


The average satisfaction rating for Biogen Idec (Nasdaq: BIIB) and Elan's (NYSE: ELN) Tysabri (natalizumab).…

AubagioBiogen IdecBiotechnologyElanGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalSanofiTysabri

European neurologists view Rxing of Biogen Idec's BG-12, Sanofi's Aubagio and Sanofi/Bayer's Lemtrada


More than 85% of surveyed neurologists in the European Union-5 (France, Germany, Italy, Spain and the…

AubagioBayerBG-12Biogen IdecBiotechnologyEuropeLemtradaMarkets & MarketingNeurologicalPharmaceuticalSanofi

Reimbursement outlook for DMT Alzheimer's therapies in Europe


Emerging potentially disease-modifying therapies (DMTs) for Alzheimer's disease will likely be reimbursed…

BiotechnologyEuropeMarkets & MarketingNeurologicalPharmaceuticalPricing

Drug shortages spur developments in neurometabolic treatments


A prolonged gap in the neurology market following the shutdown of a Genzyme production facility is tempting…

BiotechnologyMarkets & MarketingNeurologicalPharmaceuticalRare diseasesResearch

Back to top